Prostamax

Prostamax is a peptide marketed for prostate health and general men's health. It's a synthetic short peptide from the Russian 'Khavinson' bioregulator family, associated with the prostate. It is not an FDA-approved drug, and the evidence comes only from cell studies and one rat study, not humans, with no large controlled trials.

Prostamax is marketed for prostate health, but the research is laboratory-only. Most studies looked at effects on DNA packaging (chromatin) in human cells — small structural changes and increased gene accessibility in cells from elderly donors. One study looked at prostate tissue itself: in rat prostate kept alive in culture, the peptide stimulated explant growth in young and old animals. These are all findings from one research lineage; there are no large controlled human trials showing Prostamax treats prostate problems or any condition.

Not a drug in the US and not FDA-approved for any indication. A synthetic "Khavinson" short-peptide bioregulator ("cytogen") from the St. Petersburg Institute of Bioregulation and Gerontology (Russia), associated with the prostate. Evidence is almost entirely preclinical (cell/chromatin) plus small Russian studies; no large controlled human trials. WADA: not specifically named; best treated as S0 (non-approved), prohibited at all times — verify with your anti-doping organization. Not DEA-scheduled.

Prostamax has essentially no controlled human safety data and is not FDA-approved. It is not a treatment for any prostate condition — prostate symptoms warrant a clinician, since some are serious. As a non-approved research peptide it is best treated as prohibited in regulated sport (WADA S0). VialWise is a research and educational reference, not medical advice.

⚠️ For research and educational purposes only. Prostamax is not FDA-approved and is not a treatment for prostate enlargement, prostatitis, or any condition. Its evidence is preclinical. Information here is informational, not medical advice.

⚠️ Part of the Khavinson "bioregulator" family — read the shared caveat. Prostamax is one of a set of short peptides from the St. Petersburg Institute of Bioregulation and Gerontology, sharing a thin, mostly-preclinical, largely single-institute evidence base and no large controlled human trials.[²]

⚠️ Prostate symptoms can be serious. Urinary or prostate symptoms should be evaluated by a clinician — some causes (including prostate cancer) require prompt diagnosis. Do not substitute an unproven peptide for medical evaluation.

Prostamax is the synthetic tetrapeptide Lys-Glu-Asp-Pro (KEDP)[³] in the "Khavinson" bioregulator family, associated with the prostate. According to PubMed, Prostamax has been studied mainly at the chromatin level: - It caused a redistribution of thermal-denaturation profiles and small structural changes in the packaging of human-lymphocyte chromatin.[¹] - With Vilon, Epithalon, Livagen, and Cortagen, it was among short peptides that activated ribosomal genes and decondensed chromatin in lymphocytes from people aged 75–88, and it was one of three that decondensed chromosome 1 pericentromeric chromatin.[²] - In cells from donors aged 75–86, it was reported to raise sister-chromatid exchanges from about 5.9 to 12.0 per cell and Ag-positive nucleolar organizer regions from about 0.95 to 2.5 per cell, and to reduce large pericentromeric heterochromatin segments on chromosomes 1 and 9.[³] This paper's title states the sequence "(Lys-Glu-Asp-Pro)" — the primary-source confirmation of the compound's identity. - A microcalorimetry study examined lymphocyte-culture chromatin thermal stability in the presence of copper, cadmium, and prostamax; the effects the abstract reports are attributed to the Cu(II) and Cd(II) ions, not to prostamax.[⁴]

One study did look at prostate tissue. In organotypic tissue culture, prostamax (with cardiogen, bronchogen, and pancragen) at 0.05 ng/mL stimulated growth of explants from the matching organ — prostate — in both 3-week-old and 18-month-old rats, compared with control explants.[⁵] This is the closest primary evidence for the entry's prostate-tissue association, and it is a rat explant result, not a human outcome.

Evidence quality. Preclinical — chromatin work in cultured human lymphocytes plus one rat explant study, all from a single research lineage (Tbilisi and St. Petersburg groups). No large controlled human trials. See the shared Khavinson caveat below.

### About the Khavinson bioregulators (shared framing)

Developed from the 1970s by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, these cytomedin/cytogen peptides went from organ-extract complexes to synthetic short peptides proposed to have tissue-specific effects under a "peptide theory of ageing." Honest caveats: evidence is overwhelmingly preclinical plus small, often non-blinded Russian studies; no large independent randomized trials; none FDA-approved; sold in Russia as injectables and supplements.

Regulatory status (US). Not FDA-approved; not a drug. Not DEA-scheduled.

Regulatory status (sport — WADA). Not specifically named; best treated as S0 (non-approved), prohibited at all times. Verify with your anti-doping organization.

Common research interests. Prostate/men's-health support (its associated organ). Extrapolated from preclinical data, not an established human use.

Commonly reported

• Injection-site reactions
• Reactions to research-supply material of variable purity
• Gene-accessibility effects. Prostamax alters chromatin in vitro;[¹][²] long-term consequences in humans are uncharacterized.
• Unknown long-term safety.

Not a treatment for any prostate condition — see a clinician; prostate symptoms need proper evaluation

Pregnancy and lactation — not applicable/no data

Pediatric use — no data; not for researchers under 18

Active malignancy (including prostate cancer) — caution; effects of gene-activity-modulating peptides in the cancer context are uncharacterized

Known hypersensitivity — contraindicated

Regulatory note (US): Not FDA-approved; not DEA-scheduled.

Regulatory note (sport): Best treated as WADA S0. Verify with your anti-doping organization.

Bioregulator (Khavinson peptide)

A very short synthetic peptide from the St. Petersburg Institute of Bioregulation and Gerontology, each linked to an organ — here, the prostate.

Heterochromatin

Tightly packed, mostly silent DNA. Prostamax caused small structural changes to it in the lab.

Prostate

A male reproductive gland; the tissue this peptide is associated with.

Preclinical

Research in cells or animals, before human testing.

1. Meskhi T, Khachidze D, Barbakadze Sh, Madzhagaladze G, Gorgoshidze M, Monaselidze D, Lezhava T, Tadumadze N. (2004). [The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ]. Biofizika, 49(6):1091–1093.(PMID 15612551)
2. Khavinson VKh, Lezhava TA, Malinin VV. (2004). Effects of short peptides on lymphocyte chromatin in senile subjects. Bulletin of Experimental Biology and Medicine, 137(1):78–81.(PMID 15085253)
3. Dzhokhadze TA, Buadze TZh, Gaĭozishvili MN, Baratashvili NA, Lezhava TA. (2012). [Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)]. Georgian Medical News, (212):76–82. Russian-language; no DOI indexed.(PMID 23221144)
4. Kiladze M, Gorgoshidze M, Monaselidze J, Jokhadze T, Lezhava T. (2009). Microcalorimetric study of human blood lymphocytes culture at presence of copper, cadmium and prostamax. Georgian Medical News, (168):104–7. English-language; no DOI indexed.(PMID 19359734)
5. Zakutskiĭ AN, Chalisova NI, Ryzhak GA, Aniskina AI, Filippov SV, Zeziulin PN. (2006). [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats]. Advances in Gerontology, 19:93–6. Russian-language; no DOI indexed.(PMID 17152728)

• Bronchogen — same mechanism class
• Cardiogen — same mechanism class
• Cartalax — same mechanism class
• Chonluten — same mechanism class
• Cortagen — same mechanism class
• Crystagen — same mechanism class